Compare EDUC & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | XAIR |
|---|---|---|
| Founded | 1965 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 10.5M |
| IPO Year | N/A | N/A |
| Metric | EDUC | XAIR |
|---|---|---|
| Price | $1.28 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 43.4K | ★ 174.9K |
| Earning Date | 01-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,415,900.00 | $5,802,000.00 |
| Revenue This Year | N/A | $128.45 |
| Revenue Next Year | N/A | $153.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $0.92 | $1.00 |
| 52 Week High | $1.95 | $11.20 |
| Indicator | EDUC | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 33.28 |
| Support Level | $1.21 | $1.00 |
| Resistance Level | $1.35 | $1.38 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 57.87 | 35.29 |
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.